Codice QR

The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking

Several tumor types have been efficiently treated with PARP inhibitors (PARPis), which are now approved for the treatment of ovarian, breast, prostate, and pancreatic cancers. The <i>BRCA1/2</i> genes and mutations in many additional genes involved in the HR pathway may be responsible for the HRD ph...

Descrizione completa

Salvato in:
Autori principali: Aikaterini Tsantikidi, Eirini Papadopoulou, Vasiliki Metaxa-Mariatou, George Kapetsis, Georgios Tsaousis, Angeliki Meintani, Chrysiida Florou-Chatzigiannidou, Maria Gazouli, Christos Papadimitriou, Eleni Timotheadou, Athanasios Kotsakis, Anastasios Boutis, Ioannis Boukovinas, Eleftherios Kampletsas, Loukas Kontovinis, Elena Fountzilas, Charalampos Andreadis, Charisios Karanikiotis, Dimitrios Filippou, Georgios Theodoropoulos, Mustafa Özdoğan, George Nasioulas
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI AG 2023-09-01
Serie:Diagnostics
Soggetti:
DNA repair
homologous recombination deficiency
biomarkers
precision oncology
loss of heterozygosity
poly (ADP-ribose) polymerase (PARP) inhibitors
Accesso online:https://www.mdpi.com/2075-4418/13/18/2962
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi